CCL23 and ovarian carcinoma: Drug repositioning is a method used to discover the novel uses of approved drugs through the PPI network.[42] Shahjaman et al predicted 16 small-molecule drugs for the treatment of ovarian cancer by constructing a PPI network of DEGs.[43] Wang et al identified 15 drugs suitable for treating melanoma by constructing a PPI network of hub genes in the co-expression network.[44] Based on the PPI network of CCL23 and HNF1B, we identified that artenimol and pascolizumab may be appropriate for the treatment of patients with LUSC.